AGL at a glance
agilon health, inc. (AGL, SEC CIK 1831097) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as August 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), agilon health, inc. (AGL) reported revenue of $5.9 billion (down 2.1% from FY2024) and a net loss of $391.3 million.
- As of December 31, 2025, 25 institutional investment managers tracked by SignalX reported holding agilon health, inc. (AGL) shares worth $114.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.9B
- −2.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $114.2M · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability or margin percentages disclosed in the excerpt
- Headwinds: medical costs exceeding revenue, membership reductions, payor dependence, healthcare regulation, management transition risks
Risk Factors
- No material changes to 10-K risk factors for quarter ended June 30, 2026
- No newly added risk factor or triggering event disclosed
- No material regulatory, legal, compliance, operational, competitive, market, or financial risk updates disclosed
AI summary of the AGL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results released for periods ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed operating and financial results
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CTO Girish Venkatachaliah departing August 1, 2026, creating technology leadership transition risk
- Twelve-month cash severance totaling $766,063
Item 5.07: Submission of Matters to a Vote of Security Holders
- All three Class II director nominees elected, serving through the 2029 annual meeting
- Diana McKenzie strongest support with 11,679,958 votes for and 177,760 against
AI summaries of AGL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AGL
Don't miss the next AGL filing
- Alerts as it files. A push when AGL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AGL, by share count.
- Ask anything. An AI agent that reads every AGL filing and answers with sources.
AGL alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gertsch Timothy | F | Aug 16, 2026 | 17 | $96.90 |
| Zamore Denise | F | Aug 1, 2026 | 37 | $91.61 |
| Schwaneke Jeffrey A. | F | Jul 1, 2026 | 2,311 | $111.74 |
| Battaglia Silvana | A | Jun 2, 2026 | 2,133 | - |
| WILLIAMS RONALD A | A | Jun 2, 2026 | 2,133 | - |
| Mansukani Sharad | A | Jun 2, 2026 | 2,133 | - |
| McLoughlin Karen | A | Jun 2, 2026 | 2,133 | - |
| MCKENZIE DIANA | A | Jun 2, 2026 | 2,133 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $4.3B | $6.1B | $5.9B |
| Operating Income | -$232.1M | -$292.1M | -$463.2M |
| Net Income | -$262.6M | -$260.2M | -$391.3M |
| Op. Margin | -5.4% | -4.8% | -7.8% |
| Net Margin | -6.1% | -4.3% | -6.6% |
| Balance Sheet | |||
| Total Assets | $1.7B | $1.7B | $1.3B |
| Equity | - | $471.0M | $126.7M |
| ROE | - | -55.2% | -308.8% |
| Cash Flow | |||
| Operating CF | -$156.2M | -$57.8M | -$105.8M |
| CapEx | $15.8M | $13.3M | $13.2M |
Source: XBRL data in agilon health, inc. (AGL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q4 2025Aggregate AGL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q4 2025 | 25 | $114.2M |
| Q3 2025 | 24 | $177.5M |
| Q2 2025 | 27 | $423.8M |
| Q1 2025 | 24 | $603.3M |
| Q4 2024 | 21 | $124.4M |
| Q3 2024 | 17 | $72.2M |
- Goldman Sachs Group+13.28M (+196%)
- D.E. Shaw & Co+10.32M (+103%)
- AQR Capital Management+9.51M (+1347%)
- Renaissance Technologies LLC+911.4K (+62%)
- Invesco Ltd+236.0K (+31%)
- FMR LLC (Fidelity)−12.76M (-82%)
- Vanguard Group Inc−5.97M (-25%)
- Morgan Stanley−5.51M (-9%)
- Bank of America Corp−5.13M (-95%)
- JPMorgan Chase & Co−3.72M (-88%)
- Two Sigma Investments+1.11M
- Raymond James Financial+36.0K
- Citizens Financial Group−10.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 138 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AGL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Aug 4, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| SC 13G | May 14, 2026 | - | - | |
| SC 13G | May 13, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 27, 2026 | - | Analysis | - |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
| 4 | Apr 16, 2026 | - | - | - |
Related Health Care companies
- DVA · DaVitaServices-Misc Health & Allied Services, NEC
- PGNY · Progyny, Inc.Services-Misc Health & Allied Services, NEC
- VMD · VIEMED HEALTHCARE, INC.Services-Misc Health & Allied Services, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
AGL SEC filings: frequently asked questions
Which institutions hold AGL stock?
As of December 31, 2025, the largest agilon health, inc. (AGL) holders among the 13F filers tracked by SignalX were Morgan Stanley ($37.1 million), BlackRock ($15.6 million), D.E. Shaw & Co ($14.0 million), Goldman Sachs Group ($13.8 million), Vanguard Group Inc ($12.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AGL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), agilon health, inc. (AGL) reported revenue of $5.9 billion (down 2.1% from FY2024) and a net loss of $391.3 million. The figures come from the XBRL data in the 10-K.
What did AGL report in its latest 8-K?
agilon health, inc. (AGL) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 and first-half 2026 financial results released for periods ended June 30, 2026.
What are the latest AGL SEC filings?
agilon health, inc. (AGL) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on August 18, 2026.
What is AGL's SEC CIK number?
agilon health, inc. (AGL)'s SEC Central Index Key (CIK) is 1831097. EDGAR lists every AGL filing under that number.
Ask anything about AGL
The research agent reads AGL's filings, financials, insider trades and 13F holders, then answers with sources.